Brief: Basilea Announces Positive Data On Derazantinib As Monotherapy In iCCA

Basilea Pharmaceutica AG, Allschwil

31/05/2021 07:19

May 31 (Reuters) - BASILEA PHARMACEUTICA AG  BSLN.S :
    * POSITIVE EFFICACY DATA FURTHER SUBSTANTIATE THE CLINICAL
PROOF-OF-CONCEPT OF DERAZANTINIB AS MONOTHERAPY IN ICCA

Source text for Eikon:  ID:nGNEBpYPL 
Further company coverage:  BSLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))